Tesaro’s (TSRO) Buy Rating Reiterated at Lake Street Capital
Lake Street Capital reiterated their buy rating on shares of Tesaro Inc. (NASDAQ:TSRO) in a research report report published on Monday. They currently have a $150.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $114.00.
Several other equities research analysts also recently commented on TSRO. Robert W. Baird started coverage on shares of Tesaro in a research report on Monday, July 18th. They set an outperform rating and a $105.00 target price on the stock. Mizuho cut their target price on shares of Tesaro from $100.00 to $94.00 and set a buy rating on the stock in a research report on Friday, August 5th. Wedbush reiterated a buy rating on shares of Tesaro in a research report on Friday, August 5th. Jefferies Group set a $80.00 target price on shares of Tesaro and gave the stock a hold rating in a research report on Friday, August 5th. Finally, Credit Suisse Group AG reiterated a buy rating on shares of Tesaro in a research report on Friday, August 5th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and thirteen have assigned a buy rating to the company. Tesaro has a consensus rating of Buy and an average target price of $113.97.
Shares of Tesaro (NASDAQ:TSRO) opened at 135.63 on Monday. The company’s market cap is $7.01 billion. Tesaro has a 1-year low of $29.51 and a 1-year high of $138.50. The company has a 50-day moving average of $113.35 and a 200-day moving average of $81.04.
Tesaro (NASDAQ:TSRO) last posted its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($1.98) EPS for the quarter, missing the consensus estimate of ($1.92) by $0.06. Tesaro had a negative return on equity of 141.88% and a negative net margin of 798.68%. The business had revenue of $3.73 million for the quarter, compared to analyst estimates of $4.39 million. During the same quarter in the prior year, the business earned ($1.66) earnings per share. The firm’s quarterly revenue was up 4187.4% on a year-over-year basis. Equities analysts forecast that Tesaro will post ($7.42) EPS for the current year.
In other Tesaro news, SVP Martin H. Jr. Huber sold 327 shares of the business’s stock in a transaction on Wednesday, November 2nd. The shares were sold at an average price of $121.29, for a total transaction of $39,661.83. Following the completion of the sale, the senior vice president now owns 1,842 shares in the company, valued at approximately $223,416.18. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Jeffrey H. Hanke sold 29,166 shares of the business’s stock in a transaction on Tuesday, August 30th. The shares were sold at an average price of $86.04, for a total transaction of $2,509,442.64. Following the sale, the vice president now owns 29,166 shares of the company’s stock, valued at approximately $2,509,442.64. The disclosure for this sale can be found here. 40.50% of the stock is currently owned by insiders.
Hedge funds have recently made changes to their positions in the stock. CenturyLink Investment Management Co acquired a new stake in shares of Tesaro during the third quarter worth approximately $172,000. KCG Holdings Inc. acquired a new stake in shares of Tesaro during the second quarter worth approximately $228,000. Amalgamated Bank acquired a new stake in shares of Tesaro during the second quarter worth approximately $260,000. Quantitative Systematic Strategies LLC acquired a new stake in shares of Tesaro during the second quarter worth approximately $240,000. Finally, M&T Bank Corp acquired a new stake in shares of Tesaro during the third quarter worth approximately $299,000. Institutional investors and hedge funds own 88.96% of the company’s stock.
Tesaro Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.
Receive News & Stock Ratings for Tesaro Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tesaro Inc. and related stocks with our FREE daily email newsletter.